Silexion Therapeutics (NASDAQ:SLXN) Trading Up 0.4% – What’s Next?

Silexion Therapeutics Corp (NASDAQ:SLXN) shares shot up 0.4% on Thursday . The stock traded as high as $0.98 and last traded at $0.96. 155,361 shares traded hands during trading, a decline of 97% from the average session volume of 5,339,832 shares. The stock had previously closed at $0.96.

Analyst Upgrades and Downgrades

Separately, Maxim Group decreased their price target on Silexion Therapeutics from $9.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th.

Silexion Therapeutics Trading Up 0.4%

The company has a 50-day moving average price of $0.99 and a two-hundred day moving average price of $1.62.

Silexion Therapeutics (NASDAQ:SLXN) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Silexion Therapeutics stock. Meyer Handelman Co. acquired a new position in shares of Silexion Therapeutics Corp (NASDAQ:SLXN) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 32,967 shares of the company’s stock, valued at approximately $36,000. Meyer Handelman Co. owned approximately 0.39% of Silexion Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 10.95% of the company’s stock.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.